Article

In vitro response of osteoarthritic chondrocytes and fibroblast-like synoviocytes to a 500-730 kDa hyaluronan amide derivative.

Department of Biomedical Sciences, University of Padova, Italy. .
Journal of Biomedical Materials Research Part B Applied Biomaterials (impact factor: 2.15). 08/2012; 100(8):2073-81. DOI:10.1002/jbm.b.32771 pp.2073-81
Source: PubMed

ABSTRACT The aim of this study was to compare the effects of native hyaluronan (HA) with that of its hexadecylamide derivative (HYADD) on proliferation of fibroblast-like synoviocytes (FLS) and chondrocytes. The production of inflammatory and anti-inflammatory cytokines was also analyzed in FLS cultures. The proliferation of osteoarthritis (OA) chondrocytes was enhanced when cells were treated with 0.5-1.5 mg mL(-1) of HA or HYADD®4-G. This effect was completely suppressed by the anti-CD44 antibody. At 0.5 to 1 mg mL(-1) , HA and HYADD®4-G did not influence the proliferation of normal or pathological FLS; however, at the higher concentration (1.5 mg mL(-1) ), HYADD®4-G did significantly inhibit cell proliferation. As to effects on inflammation, a significant increase in the expression of the IL-10 gene was observed when FLS were pretreated with tumor necrosis factor alpha and then cultured in the presence of 0.5 mg mL(-1) HYADD® 4-G or HA. The effects of HA derivatives on FLS proliferation and production of anti-inflammatory cytokines indicate that they may be of therapeutic benefit in OA. The longer residence time in the joint cavity, the increased viscoelasticity, and the anti-inflammatory potential of HYADD®4-G make it a better candidate than native HA for OA therapy. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012.

0 0
 · 
0 Bookmarks
 · 
41 Views

Keywords

anti-inflammatory cytokines
 
anti-inflammatory potential
 
Appl Biomater
 
fibroblast-like synoviocytes
 
FLS cultures
 
FLS proliferation
 
hexadecylamide derivative
 
higher concentration
 
HYADD®4-G
 
IL-10 gene
 
increased viscoelasticity
 
J Biomed Mater Res Part B
 
joint cavity
 
native hyaluronan
 
OA therapy
 
osteoarthritis
 
pathological FLS
 
therapeutic benefit
 
tumor necrosis factor alpha
 
© 2012 Wiley Periodicals